Hematology continues to evolve at pace, with innovative therapies transforming the management of both malignant and non-malignant blood disorders. At APLUSA, we have developed deep expertise in this area through decades of specialized market research and patient-level data collection. Our syndicated trackers, patient chart studies, and advanced methodologies shed light on physician decision-making, treatment sequencing, and market adoption in conditions ranging from lymphomas to bleeding disorders.

Whether supporting early-stage strategy, preparing for launch, or monitoring in-market performance, we help clients cut through complexity to anticipate trends and identify opportunities.

Some of the areas we’ve explored

• Multiple Myeloma
• DLBCL
• Beta-Thalassemia
• Biosimilars vs. Branded in Hematology (MCL)
• CLL & FL
• Hemophilia A & B
• ITP (Immune Thrombocytopenic Purpura)
• PNH (Paroxysmal Nocturnal Hemoglobinuria)